Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Affymetrix and Tessare Develop Pathogen-Detection Kit

By HospiMedica staff writers
Posted on 12 Feb 2007
Affymetrix Inc. More...
(Santa Clara, CA, USA) announced that it has granted Tessare, Inc. (Colorado Springs, CO, USA) non-exclusive access to its microarray technology to develop and market epidemiological tests for public health and biodefense surveillance.

As part of the Powered by Affymetrix program, the TessArray kits will detect and identify hundreds of strains of natural and emergent viral and bacterial pathogens, as well as biothreat agents. The resulting information will enable scientists to understand and respond to pandemic infectious disease threats.

The TessArray kits are based on multiplexed genotypic signatures present on the Affymetrix CustomSeq Resequencing Arrays. These arrays have been designed and fabricated to detect a set of upper respiratory pathogen-specific target sequences provided by the U.S. Naval Research Laboratory. Public health officials can use the resulting information to identify the most likely agent strain(s) associated with disease outbreaks.

Tessare president and co-founder Klaus Schafer, M.D., M.P.H., said, Investigators at collection sites can determine whether detected pathogen strains warrant elevated epidemic or pandemic concerns. The TessArray kits enable a level of strain and sub-strain discrimination not possible with other array-based methodologies, as well as the ability to detect and characterize novel nucleotide changes in the pathogen genome sequence at the same time.

With the recent emergence of new infectious diseases such as avian influenza, it is important for global health organizations to have access to comprehensive epidemiological surveillance research tools, said Robert Lipshutz, Ph.D., senior vice president, corporate development and emerging markets at Affymetrix. We are pleased to have Tessare join our Powered by Affymetrix program and we anticipate that the availability of these types of microarray-based testing kits and services will allow epidemiologists to better monitor the spread of pathogens and detect mutations that may alter their potential to cause a pandemic.






Related Links:
Tessare
Affymetrix

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Multi-Chamber Washer-Disinfector
WD 390
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.